MX2015012760A - Composicion farmaceutica que comprende un activador de ampk y un agente serotonergico y metodos de uso de la misma. - Google Patents
Composicion farmaceutica que comprende un activador de ampk y un agente serotonergico y metodos de uso de la misma.Info
- Publication number
- MX2015012760A MX2015012760A MX2015012760A MX2015012760A MX2015012760A MX 2015012760 A MX2015012760 A MX 2015012760A MX 2015012760 A MX2015012760 A MX 2015012760A MX 2015012760 A MX2015012760 A MX 2015012760A MX 2015012760 A MX2015012760 A MX 2015012760A
- Authority
- MX
- Mexico
- Prior art keywords
- pharmaceutical composition
- methods
- agent
- ampk activator
- diseases
- Prior art date
Links
- 239000003795 chemical substances by application Substances 0.000 title abstract 3
- MPLLLQUZNJSVTK-UHFFFAOYSA-N 5-[3-[4-[2-(4-fluorophenyl)ethoxy]phenyl]propyl]furan-2-carboxylic acid Chemical compound O1C(C(=O)O)=CC=C1CCCC(C=C1)=CC=C1OCCC1=CC=C(F)C=C1 MPLLLQUZNJSVTK-UHFFFAOYSA-N 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 230000000862 serotonergic effect Effects 0.000 title 1
- 201000010099 disease Diseases 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 208000001145 Metabolic Syndrome Diseases 0.000 abstract 2
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 abstract 2
- YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000003463 hyperproliferative effect Effects 0.000 abstract 1
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 abstract 1
- 229960003987 melatonin Drugs 0.000 abstract 1
- 229960004329 metformin hydrochloride Drugs 0.000 abstract 1
- OETHQSJEHLVLGH-UHFFFAOYSA-N metformin hydrochloride Chemical compound Cl.CN(C)C(=N)N=C(N)N OETHQSJEHLVLGH-UHFFFAOYSA-N 0.000 abstract 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin hydrochloride Natural products CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 abstract 1
- 229940076279 serotonin Drugs 0.000 abstract 1
- 230000002195 synergetic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Reproductive Health (AREA)
- Physical Education & Sports Medicine (AREA)
- Emergency Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Gynecology & Obstetrics (AREA)
- Rheumatology (AREA)
- Virology (AREA)
- AIDS & HIV (AREA)
- Cardiology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Hospice & Palliative Care (AREA)
- Child & Adolescent Psychology (AREA)
- Pregnancy & Childbirth (AREA)
- Psychiatry (AREA)
- Oncology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361793407P | 2013-03-15 | 2013-03-15 | |
| PCT/US2014/028413 WO2014144130A2 (en) | 2013-03-15 | 2014-03-14 | Pharmaceutical composition comprising an ampk activator and a serotonergic agent and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2015012760A true MX2015012760A (es) | 2016-06-17 |
Family
ID=51538303
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015012760A MX2015012760A (es) | 2013-03-15 | 2014-03-14 | Composicion farmaceutica que comprende un activador de ampk y un agente serotonergico y metodos de uso de la misma. |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20140350064A1 (OSRAM) |
| EP (1) | EP2983473A4 (OSRAM) |
| JP (1) | JP2016513734A (OSRAM) |
| KR (1) | KR20160005341A (OSRAM) |
| CN (1) | CN105636438A (OSRAM) |
| AR (1) | AR095631A1 (OSRAM) |
| AU (1) | AU2014227807B2 (OSRAM) |
| BR (1) | BR112015023922A2 (OSRAM) |
| CA (1) | CA2909633A1 (OSRAM) |
| CL (1) | CL2015002680A1 (OSRAM) |
| HK (1) | HK1222297A1 (OSRAM) |
| IL (1) | IL241587B (OSRAM) |
| MX (1) | MX2015012760A (OSRAM) |
| RU (1) | RU2015143438A (OSRAM) |
| TW (1) | TW201444552A (OSRAM) |
| WO (1) | WO2014144130A2 (OSRAM) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20180071269A1 (en) * | 2015-08-12 | 2018-03-15 | Tianxin Wang | Therapeutical methods, formulations and nutraceutical formulations |
| ES2567105B1 (es) * | 2014-09-19 | 2017-02-10 | Consejo Superior De Investigaciones Científicas (Csic) | Derivados de indol para la prevención y/o tratamiento de diabetes ytrastornos metabólicos relacionados |
| WO2016126662A1 (en) * | 2015-02-03 | 2016-08-11 | Kardiatonos, Inc. | Compounds for the prevention and treatment of vascular disease |
| US10463649B2 (en) | 2015-06-08 | 2019-11-05 | Texas Tech University System | Inhibitors of Mc1-1 as drugs to overcome resistance to BRAF inhibitors and MEK inhibitors |
| WO2017018752A1 (ko) * | 2015-07-29 | 2017-02-02 | 고려대학교 산학협력단 | 부스피론 유도체 및 이를 함유하는 약학 조성물 |
| KR101663543B1 (ko) * | 2015-07-29 | 2016-10-07 | 고려대학교 산학협력단 | 부스피론 유도체 및 이를 함유하는 약학 조성물 |
| US10357466B2 (en) * | 2015-08-01 | 2019-07-23 | Stephen J. Petti | Compositions and methods for combination pharmacological treatments to induce a prolonged, mild decrease in core body temperature |
| CN105541665A (zh) * | 2016-02-18 | 2016-05-04 | 江苏大学 | 一种抗肿瘤药物化合物及制备方法和应用 |
| KR101838622B1 (ko) * | 2016-09-20 | 2018-03-14 | 김브라이언 | 아디포넥틴 수용체에 대한 작용제 펩타이드 |
| US11040935B2 (en) | 2016-10-05 | 2021-06-22 | University of Pittsburgh—of the Commonwealth System of Higher Education | Small molecule AMPK activators |
| EP3338768B1 (en) | 2016-12-20 | 2019-10-30 | LTS Lohmann Therapie-Systeme AG | Transdermal therapeutic system containing asenapine |
| KR102614709B1 (ko) | 2016-12-20 | 2023-12-18 | 에르테에스 로만 테라피-시스테메 아게 | 아세나핀 및 폴리실록산 또는 폴리이소부틸렌을 함유하는 경피흡수 치료 시스템 |
| US11033512B2 (en) | 2017-06-26 | 2021-06-15 | Lts Lohmann Therapie-Systeme Ag | Transdermal therapeutic system containing asenapine and silicone acrylic hybrid polymer |
| CN107252425A (zh) * | 2017-07-12 | 2017-10-17 | 上海华堇生物技术有限责任公司 | 去氢延胡索素的药物用途 |
| US11723894B2 (en) * | 2017-10-26 | 2023-08-15 | Terran Biosciences, Inc. | Combination product for the treatment of neurological and/or psychiatric disorders |
| US11103465B2 (en) | 2017-11-22 | 2021-08-31 | Ted's Brain Science, Inc. | Trans-resveratrol topical medication for the treatment of pain and method of manufacture thereof |
| US11208475B1 (en) * | 2018-01-30 | 2021-12-28 | Flagship Pioneering Innovations V, Inc. | Methods and compositions for treating inflammatory or autoimmune diseases or conditions using serotonin receptor activators |
| CN108159044A (zh) * | 2018-02-26 | 2018-06-15 | 华中科技大学 | 抗坏血酸与二甲双胍的复合制剂用于制备化疗药物的应用 |
| US12329862B2 (en) | 2018-06-20 | 2025-06-17 | Lts Lohmann Therapie-Systeme Ag | Transdermal therapeutic system containing asenapine |
| AU2019291060B2 (en) | 2018-06-20 | 2024-09-05 | Lts Lohmann Therapie-Systeme Ag | Transdermal therapeutic system containing asenapine |
| CN108997172B (zh) * | 2018-08-08 | 2020-12-15 | 中国人民解放军总医院 | 抗肿瘤化合物 |
| WO2020087031A1 (en) | 2018-10-26 | 2020-04-30 | The Research Foundation For The State University Of New York | Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia |
| CN109771424B (zh) * | 2019-03-11 | 2021-03-16 | 马慧 | 一种防治老年ⅱ型糖尿病性骨质疏松症的药物组合物及其应用 |
| CN109793727A (zh) * | 2019-03-13 | 2019-05-24 | 湖北科技学院 | 一种有效抗恶性肿瘤的药物组合物及其应用 |
| WO2021050538A1 (en) | 2019-09-10 | 2021-03-18 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Methods and materials for increasing level of phosphorylated ampk protein |
| CN110559298A (zh) * | 2019-10-28 | 2019-12-13 | 中国药科大学 | 一种天然化合物Egenine用于制备抗肾纤维化药物的用途 |
| WO2021086133A1 (ko) * | 2019-10-31 | 2021-05-06 | (주)제이디바이오사이언스 | 삼환식 화합물 및 이의 약학적 용도 |
| CN115667217A (zh) | 2020-05-19 | 2023-01-31 | 赛本爱尔兰有限公司 | 氘化的色胺衍生物和使用方法 |
| WO2022017440A1 (zh) * | 2020-07-22 | 2022-01-27 | 山东绿叶制药有限公司 | 5-ht 2a受体抑制剂或反向激动剂及其制备方法和应用 |
| US20240208923A1 (en) * | 2021-03-10 | 2024-06-27 | Jnana Therapeutics Inc. | Small molecule inhibitors of mammalian slc6a19 function |
| WO2023283364A2 (en) | 2021-07-07 | 2023-01-12 | Terran Biosciences Inc. | N,n-dimethyltryptamine and related psychedlics and uses thereof |
| CA3237988A1 (en) | 2021-11-12 | 2023-05-19 | Terran Biosciences Inc. | Psilocybin and o-acetylpsilocin, salts and solid state forms thereof |
| WO2024123825A1 (en) * | 2022-12-05 | 2024-06-13 | Enveda Therapeutics, Inc. | Nootkatone for the treatment of psoriasis or atopic dermatitis |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3174901A (en) * | 1963-01-31 | 1965-03-23 | Jan Marcel Didier Aron Samuel | Process for the oral treatment of diabetes |
| EP1762234A4 (en) * | 2004-06-28 | 2010-05-05 | Kao Corp | AMPK AKTIVATOR |
| US20070149466A1 (en) * | 2005-07-07 | 2007-06-28 | Michael Milburn | Methods and related compositions for treating or preventing obesity, insulin resistance disorders, and mitochondrial-associated disorders |
| US7754700B2 (en) * | 2006-04-24 | 2010-07-13 | Trager Seymour F | Composition and methods for alleviating symptoms of neurotoxicity |
| US20120183600A1 (en) * | 2007-01-16 | 2012-07-19 | Chien-Hung Chen | Novel composition for treating metabolic syndrome and other conditions |
| TWI629058B (zh) * | 2007-01-16 | 2018-07-11 | 陳建宏 | 醫藥組成物及其用途 |
| US20120232003A1 (en) * | 2009-03-13 | 2012-09-13 | Takahashi Joseph S | Compositions and methods for diabetes treatment |
| US8486922B2 (en) * | 2010-04-28 | 2013-07-16 | Chien-Hung Chen | Composition |
-
2014
- 2014-03-14 TW TW103109748A patent/TW201444552A/zh unknown
- 2014-03-14 US US14/212,734 patent/US20140350064A1/en not_active Abandoned
- 2014-03-14 EP EP14763798.7A patent/EP2983473A4/en not_active Withdrawn
- 2014-03-14 HK HK16109576.5A patent/HK1222297A1/zh unknown
- 2014-03-14 JP JP2016502780A patent/JP2016513734A/ja active Pending
- 2014-03-14 MX MX2015012760A patent/MX2015012760A/es unknown
- 2014-03-14 BR BR112015023922A patent/BR112015023922A2/pt not_active IP Right Cessation
- 2014-03-14 RU RU2015143438A patent/RU2015143438A/ru unknown
- 2014-03-14 CA CA2909633A patent/CA2909633A1/en not_active Abandoned
- 2014-03-14 WO PCT/US2014/028413 patent/WO2014144130A2/en not_active Ceased
- 2014-03-14 AU AU2014227807A patent/AU2014227807B2/en not_active Ceased
- 2014-03-14 CN CN201480028057.0A patent/CN105636438A/zh active Pending
- 2014-03-14 KR KR1020157029838A patent/KR20160005341A/ko not_active Withdrawn
- 2014-03-17 AR ARP140101258A patent/AR095631A1/es unknown
-
2015
- 2015-09-14 CL CL2015002680A patent/CL2015002680A1/es unknown
- 2015-09-16 IL IL241587A patent/IL241587B/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| HK1222297A1 (zh) | 2017-06-30 |
| JP2016513734A (ja) | 2016-05-16 |
| IL241587B (en) | 2019-01-31 |
| TW201444552A (zh) | 2014-12-01 |
| WO2014144130A3 (en) | 2015-02-05 |
| EP2983473A2 (en) | 2016-02-17 |
| CN105636438A (zh) | 2016-06-01 |
| AU2014227807A1 (en) | 2015-11-05 |
| WO2014144130A2 (en) | 2014-09-18 |
| CA2909633A1 (en) | 2014-09-18 |
| AR095631A1 (es) | 2015-10-28 |
| CL2015002680A1 (es) | 2016-09-02 |
| KR20160005341A (ko) | 2016-01-14 |
| AU2014227807B2 (en) | 2018-03-08 |
| RU2015143438A (ru) | 2017-04-21 |
| US20140350064A1 (en) | 2014-11-27 |
| EP2983473A4 (en) | 2016-11-23 |
| BR112015023922A2 (pt) | 2017-07-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2015012760A (es) | Composicion farmaceutica que comprende un activador de ampk y un agente serotonergico y metodos de uso de la misma. | |
| MX2022013612A (es) | Combinaciones de inhibidores de desmetilasa-1 especifica de lisina (lsd1) para el tratamiento de malignidades hematologicas. | |
| PH12017501306A1 (en) | Inhibitors of histone demethylases | |
| TW201613887A (en) | Antiproliferative compounds and methods of use thereof | |
| MX384403B (es) | Terapia de combinación para el tratamiento del cáncer. | |
| MX2013011908A (es) | Composiciones y usos terapeuticos de inhibidores de cinasa epsilon relacionados con cinasa i-kappa b (ikk) y cinasa 1 de union tank. | |
| MX383866B (es) | Inhibidores de ezh2 para tratar linfomas. | |
| JOP20130256B1 (ar) | مركبات سلفامويل اريل اميدات واستعمالها كمواد علاجية لمعالجة التهاب الكبد نوع بي | |
| AR096892A1 (es) | Una combinación farmacéutica para el tratamiento del melanoma | |
| MX2018005041A (es) | Compuestos para tratar la esclerosis lateral amiotrofica. | |
| WO2015095834A3 (en) | Cancer treatments using erk1/2 and bcl-2 family inhibitors | |
| PH12016500140A1 (en) | Heterobicycloaryl rorc2 inhibitors and methods of use thereof | |
| EA201990424A1 (ru) | Спиролактамовые модуляторы nmda-рецептора и их применение | |
| PH12015502365B1 (en) | Bace1 inhibitors | |
| EA201990428A1 (ru) | Спиролактамовые модуляторы nmda-рецептора и их применение | |
| PH12016502352A1 (en) | Pharmaceutical composition | |
| TW201613578A (en) | Pharmaceutical combinations | |
| PH12016501371A1 (en) | Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same | |
| BR112016013754A2 (pt) | Recaptação de serotonina-norepinefrina inibidores (irsns) e combinações dos ligantes do receptor sigma | |
| NZ755637A (en) | Compounds and their use in the treatment of schistosomiasis | |
| EA201891439A1 (ru) | Трициклические соединения и их композиции в качестве ингибиторов киназ | |
| AU2017258649A1 (en) | Covalent BTK inhibitors and uses thereof | |
| MX2019007360A (es) | Derivado de triazol azabiciclo-sustituido, preparacion, metodo del mismo, y aplicacion de la misma en medicina. | |
| MY206575A (en) | Isochromene derivatives as phosphoinositide 3-kinases inhibitors | |
| MX2017004322A (es) | Composicion farmaceutica que comprende aspirina, metformina y serotonina con agente tensioactivo no ionico. |